<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        19-665-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JAKAVI 20MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RUXOLITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        13769.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA SCHWEIZ AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jakavi 20 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Jakavi 20 mg tablets
Each tablet contains 20 mg ruxolitinib (as phosphate).

Excipient with known effect
Each tablet contains 285.80 mg lactose monohydrate.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jakavi 20 mg tablets
Elongated curved white to almost white tablets of approximately 16.5 x 7.4 mm with “NVR” debossed one one side and “L20” debossed on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Myelofibrosis (MF)</u></p><p>&nbsp;</p><p>Jakavi is indicated for the treatment of disease‑related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.</p><p>&nbsp;</p><p><u>Polycythaemia vera (PV)</u></p><p>&nbsp;</p><p>Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Jakavi treatment should only be initiated by a physician experienced in the administration of anti‑cancer medicinal products.</p><p>&nbsp;</p><p>A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi.</p><p>&nbsp;</p><p>Complete blood count, including a white blood cell count differential, should be monitored every 2‑4&nbsp;weeks until Jakavi doses are stabilised, and then as clinically indicated (see section&nbsp;4.4).</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u>Posology</u></p><p><em><u>Starting dose</u></em></p><p>The recommended starting dose of Jakavi in myelofibrosis (MF) is based on platelet counts (see Table&nbsp;1):</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Starting doses in myelofibrosis</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Platelet count</strong></p></td><td style="vertical-align:top"><p><strong>Starting dose</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Greater than 200,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>20&nbsp;mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>100,000 to 200,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>15&nbsp;mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>75,000 to less than 100,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>10&nbsp;mg orally twice daily</p></td></tr><tr><td style="vertical-align:top"><p>50,000 to less than 75,000/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>5&nbsp;mg orally twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>The recommended starting dose of Jakavi in polycythaemia vera (PV) is 10&nbsp;mg given orally twice daily.</p><p>&nbsp;</p><p>The recommended starting dose of Jakavi in acute and chronic graft versus host disease (GvHD) is 10&nbsp;mg given orally twice daily. Jakavi can be added to the continued use of corticosteroids and/or calcineurin inhibitors (CNIs).</p><p>&nbsp;</p><p><em><u>Dose modifications</u></em></p><p>Doses may be titrated based on efficacy and safety.</p><p>&nbsp;</p><p><em>Myelofibrosis and polycythaemia vera</em></p><p>If efficacy is considered insufficient and blood counts are adequate, doses may be increased by a maximum of 5&nbsp;mg twice daily, up to the maximum dose of 25&nbsp;mg twice daily.</p><p>&nbsp;</p><p>The starting dose should not be increased within the first four weeks of treatment and thereafter no more frequently than at 2‑week intervals.</p><p>&nbsp;</p><p>Treatment should be discontinued for platelet counts less than 50,000/mm<sup>3</sup> or absolute neutrophil counts less than 500/mm<sup>3</sup>. In PV, treatment should also be interrupted when haemoglobin is below 8&nbsp;g/dl. After recovery of blood counts above these levels, dosing may be re-started at 5&nbsp;mg twice daily and gradually increased based on careful monitoring of complete blood cell count, including a white blood cell count differential.</p><p>&nbsp;</p><p>Dose reductions should be considered if the platelet count decreases during treatment as outlined in Table&nbsp;2, with the goal of avoiding dose interruptions for thrombocytopenia.</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dosing recommendation for MF patients with thrombocytopenia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="5"><p><strong>Dose at time of platelet decline</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>25&nbsp;mg<br />twice daily</p></td><td><p>20&nbsp;mg<br />twice daily</p></td><td><p>15&nbsp;mg<br />twice daily</p></td><td><p>10&nbsp;mg<br />twice daily</p></td><td><p>5&nbsp;mg<br />twice daily</p></td></tr><tr><td><p><strong>Platelet count</strong></p></td><td colspan="5"><p><strong>New dose</strong></p></td></tr><tr><td><p>100,000 to &lt;125,000/mm<sup>3</sup></p></td><td><p>20&nbsp;mg<br />twice daily</p></td><td><p>15&nbsp;mg<br />twice daily</p></td><td><p>No change</p></td><td><p>No change</p></td><td><p>No change</p></td></tr><tr><td><p>75,000 to &lt;100,000/mm<sup>3</sup></p></td><td><p>10&nbsp;mg<br />twice daily</p></td><td><p>10&nbsp;mg<br />twice daily</p></td><td><p>10&nbsp;mg<br />twice daily</p></td><td><p>No change</p></td><td><p>No change</p></td></tr><tr><td><p>50,000 to &lt;75,000/mm<sup>3</sup></p></td><td><p>5&nbsp;mg<br />twice daily</p></td><td><p>5&nbsp;mg<br />twice daily</p></td><td><p>5&nbsp;mg<br />twice daily</p></td><td><p>5&nbsp;mg<br />twice daily</p></td><td><p>No change</p></td></tr><tr><td><p>Less than 50,000/mm<sup>3</sup></p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td><td><p>Hold</p></td></tr></tbody></table><p>&nbsp;</p><p>In PV, dose reductions should also be considered if haemoglobin decreases below 12&nbsp;g/dl and is recommended if it decreases below 10&nbsp;g/dl.</p><p>&nbsp;</p><p><em>Graft versus host disease</em></p><p>Dose reductions and temporary interruptions of treatment may be needed in GvHD-patients with thrombocytopenia, neutropenia, or elevated total bilirubin after standard supportive therapy including growth-factors, anti-infective therapies and transfusions. One dose level reduction step is recommended (10&nbsp;mg twice daily to 5&nbsp;mg twice daily or 5&nbsp;mg twice daily to 5&nbsp;mg once daily). In patients who are unable to tolerate Jakavi at a dose of 5&nbsp;mg once daily, treatment should be interrupted. Detailed dosing recommendations are provided in Table&nbsp;3.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dosing recommendations during ruxolitinib therapy for GvHD patients with thrombocytopenia, neutropenia or elevated total bilirubin</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1185px"><tbody><tr><td><p><strong>Laboratory parameter</strong></p></td><td style="width:1083px"><p><strong>Dosing recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Platelet count &lt;20,000/mm<sup>3</sup></p></td><td style="vertical-align:top; width:1083px"><p>Reduce Jakavi by one dose level. If platelet count &ge;20,000/mm<sup>3</sup> within seven days, dose may be increased to initial dose level, otherwise maintain reduced dose.</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count &lt;15,000/mm<sup>3</sup></p></td><td style="vertical-align:top; width:1083px"><p>Hold Jakavi until platelet count &ge;20,000/mm<sup>3</sup>, then resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count (ANC) &ge;500/mm<sup>3</sup> to &lt;750/mm<sup>3</sup></p></td><td style="vertical-align:top; width:1083px"><p>Reduce Jakavi by one dose level. Resume at initial dose level if ANC &gt;1,000/mm<sup>3</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count &lt;500/mm<sup>3</sup></p></td><td style="vertical-align:top; width:1083px"><p>Hold Jakavi until ANC &gt;500/mm<sup>3</sup>, then resume at one lower dose level. If ANC &gt;1,000/mm<sup>3</sup>,<sup> </sup>dosing may resume at initial dose level.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Total bilirubin elevation not caused by GvHD (no liver GvHD)</p></td><td style="vertical-align:top; width:1083px"><p>&gt;3.0 to 5.0&nbsp;x&nbsp;upper limit of normal (ULN): Continue Jakavi at one lower dose level until &le;3.0&nbsp;x&nbsp;ULN.</p></td></tr><tr><td style="vertical-align:top; width:1083px"><p>&gt;5.0 to 10.0&nbsp;x&nbsp;ULN: Hold Jakavi up to 14&nbsp;days until total bilirubin &le;3.0&nbsp;x&nbsp;ULN. If total bilirubin &le;3.0&nbsp;x&nbsp;ULN dosing may resume at current dose. If not &le;3.0&nbsp;x&nbsp;ULN after 14&nbsp;days, resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top; width:1083px"><p>&gt;10.0&nbsp;x&nbsp;ULN: Hold Jakavi until total bilirubin &le;3.0&nbsp;x&nbsp;ULN, then resume at one lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin elevation caused by GvHD (liver GvHD)</p></td><td style="vertical-align:top; width:1083px"><p>&gt;3.0&nbsp;x&nbsp;ULN: Continue Jakavi at one lower dose level until total bilirubin &le;3.0&nbsp;x&nbsp;ULN.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Dose adjustment with concomitant strong CYP3A4 inhibitors or dual CYP2C9/3A4 inhibitors</u></em></p><p>When ruxolitinib is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see section&nbsp;4.5). The concomitant use of ruxolitinib with fluconazole doses greater than 200&nbsp;mg daily should be avoided.</p><p>&nbsp;</p><p>More frequent monitoring (e.g. twice a week) of haematology parameters and of clinical signs and symptoms of ruxolitinib‑related adverse drug reactions is recommended while on strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>No specific dose adjustment is needed in patients with mild or moderate renal impairment.</p><p>In patients with severe renal impairment (creatinine clearance less than 30&nbsp;ml/min) the recommended starting dose based on platelet count for MF patients should be reduced by approximately 50% to be administered twice daily. The recommended starting dose for PV and GvHD patients with severe renal impairment is 5&nbsp;mg twice daily. Patients should be carefully monitored with regard to safety and efficacy during ruxolitinib treatment.</p><p>&nbsp;</p><p>There are limited data to determine the best dosing options for patients with end‑stage renal disease (ESRD) on haemodialysis. Pharmacokinetic/pharmacodynamic simulations based on available data in this population suggest that the starting dose for MF patients with ESRD on haemodialysis is a single dose of 15‑20&nbsp;mg or two doses of 10&nbsp;mg given 12&nbsp;hours apart, to be administered post-dialysis and only on the day of haemodialysis. A single dose of 15&nbsp;mg is recommended for MF patients with platelet count between 100,000/mm<sup>3</sup> and 200,000/mm<sup>3</sup>. A single dose of 20&nbsp;mg or two doses of 10&nbsp;mg given 12&nbsp;hours apart is recommended for MF patients with platelet count of &gt;200,000/mm<sup>3</sup>. Subsequent doses (single administration or two doses of 10&nbsp;mg given 12&nbsp;hours apart) should be administered only on haemodialysis days following each dialysis session.</p><p>&nbsp;</p><p>The recommended starting dose for PV patients with ESRD on haemodialysis is a single dose of 10&nbsp;mg or two doses of 5&nbsp;mg given 12&nbsp;hours apart, to be administered post-dialysis and only on the day of haemodialysis. These dose recommendations are based on simulations and any dose modification in ESRD should be followed by careful monitoring of safety and efficacy in individual patients. No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration (see section&nbsp;5.2).</p><p>There are no data for GvHD patients with ESRD.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In MF patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily. Subsequent doses should be adjusted based on careful monitoring of safety and efficacy. The recommended starting dose is 5&nbsp;mg twice daily for PV patients. Patients diagnosed with hepatic impairment while receiving ruxolitinib should have complete blood counts, including a white blood cell count differential, monitored at least every one to two weeks for the first 6&nbsp;weeks after initiation of therapy with ruxolitinib and as clinically indicated thereafter once their liver function and blood counts have been stabilised. Ruxolitinib dose can be titrated to reduce the risk of cytopenia.</p><p>&nbsp;</p><p>In patients with mild, moderate or severe hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50% (see section&nbsp;5.2).</p><p>In patients with GvHD liver involvement and an increase of total bilirubin to &gt;3&nbsp;x&nbsp;ULN, blood counts should be monitored more frequently for toxicity and a dose reduction by one dose level is recommended.</p><p>&nbsp;</p><p><em>Elderly patients (</em><em>&ge;65&nbsp;years)</em></p><p>No additional dose adjustments are recommended for elderly patients.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Jakavi in children and adolescents aged up to 18&nbsp;years with MF and PV have not been established. No data are available (see section&nbsp;5.1).</p><p>In paediatric patients (12&nbsp;years of age and older) with GvHD, the safety and efficacy of Jakavi are supported by evidence from the randomised phase&nbsp;3 studies REACH2 and REACH3. The Jakavi dose in paediatric patients with GvHD aged 12&nbsp;years and older is the same as in adults. The safety and efficacy of Jakavi have not been established in patients less than 12&nbsp;years of age.</p><p><em><u>Treatment discontinuation</u></em></p><p>Treatment of MF and PV may be continued as long as the benefit‑risk remains positive. However the treatment should be discontinued after 6&nbsp;months if there has been no reduction in spleen size or improvement in symptoms since initiation of therapy.</p><p>It is recommended that, for patients who have demonstrated some degree of clinical improvement, ruxolitinib therapy be discontinued if they sustain an increase in their spleen length of 40% compared with baseline size (roughly equivalent to a 25% increase in spleen volume) and no longer have tangible improvement in disease‑related symptoms.</p><p>In GvHD, tapering of Jakavi may be considered in patients with a response and after having discontinued corticosteroids. A 50% dose reduction of Jakavi every two months is recommended. If signs or symptoms of GvHD reoccur during or after the taper of Jakavi, re-escalation of treatment should be considered.</p><p><u>Method of administration</u></p><p>Jakavi is to be taken orally, with or without food.</p><p>If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Pregnancy and lactation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u>Myelosuppression</u></p><p>Treatment with Jakavi can cause haematological adverse drug reactions, including thrombocytopenia, anaemia and neutropenia. A complete blood count, including a white blood cell count differential, must be performed before initiating therapy with Jakavi. Treatment should be discontinued in MF patients with platelet count less than 50,000/mm<sup>3</sup> or absoute neutrophil count less than 500/mm<sup>3</sup> (see section&nbsp;4.2).</p><p>It has been observed that MF patients with low platelet counts (&lt;200,000/mm<sup>3</sup>) at the start of therapy are more likely to develop thrombocytopenia during treatment.</p><p>Thrombocytopenia is generally reversible and is usually managed by reducing the dose or temporarily withholding Jakavi (see sections&nbsp;4.2 and 4.8). However, platelet transfusions may be required as clinically indicated.</p><p>Patients developing anaemia may require blood transfusions. Dose modifications or interruption for patients developing anaemia may also need to be considered.</p><p>Patients with a haemoglobin level below 10.0&nbsp;g/dl at the beginning of the treatment have a higher risk of developing a haemoglobin level below 8.0&nbsp;g/dl during treatment compared to patients with a higher baseline haemoglobin level (79.3% versus 30.1%). More frequent monitoring of haematology parameters and of clinical signs and symptoms of Jakavi‑related adverse drug reactions is recommended for patients with baseline haemoglobin below 10.0&nbsp;g/dl.</p><p>Neutropenia (absolute neutrophil count &lt;500) was generally reversible and was managed by temporarily withholding Jakavi (see sections&nbsp;4.2 and 4.8).</p><p>Complete blood counts should be monitored as clinically indicated and dose adjusted as required (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>Infections</u></p><p>Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with Jakavi. Patients should be assessed for the risk of developing serious infections. Physicians should carefully observe patients receiving Jakavi for signs and symptoms of infections and initiate appropriate treatment promptly. Treatment with Jakavi should not be started until active serious infections have resolved.</p><p>Tuberculosis has been reported in patients receiving Jakavi. Before starting treatment, patients should be evaluated for active and inactive (&ldquo;latent&rdquo;) tuberculosis, as per local recommendations. This can include medical history, possible previous contact with tuberculosis, and/or appropriate screening such as lung x-ray, tuberculin test and/or interferon-gamma release assay, as applicable. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferase<strong> </strong>and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi. It is recommended to screen for HBV prior to commencing treatment with Jakavi. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.</p><p>&nbsp;</p><p><u>Herpes zoster and Herpes Simplex</u></p><p>Herpes zoster infection has been reported in patients receiving Jakavi. Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.</p><p>Herpes simplex virus reactivation and/or dissemination has been reported in patients receiving Jakavi [see undesirable effects 4.8]. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment with Jakavi; patients should be promptly treated and monitored according to clinical guidelines</p><p>&nbsp;</p><p><u>Progressive multifocal leukoencephalopathy</u></p><p>Progressive multifocal leukoencephalopathy (PML) has been reported with Jakavi treatment. Physicians should be particularly alert to symptoms suggestive of PML that patients may not notice (e.g., cognitive, neurological or psychiatric symptoms or signs). Patients should be monitored for any of these new or worsening symptoms or signs, and if such symptoms/signs occur, referral to a neurologist and appropriate diagnostic measures for PML should be considered. If PML is suspected, further dosing must be suspended until PML has been excluded.</p><p>&nbsp;</p><p><u>Lipid abnormalities/elevations</u></p><p>Treatment with Jakavi has been associated with increases in lipid parameters including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.</p><p>&nbsp;</p><p><u>Major adverse cardiac events (MACE)</u></p><p>In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of MACE, defined as cardiovascular death, non fatal myocardial infarction (MI) and non-fatal stroke, was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors.</p><p>MACE have been reported in patients receiving Jakavi. Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered particularly in patients 65 years of age and older, patients who are current or past long time smokers, and patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.</p><p>&nbsp;</p><p><u>Thrombosis</u></p><p>In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a dose dependent higher rate of venous thromboembolic events (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed with tofacitinib compared to TNF inhibitors.</p><p>Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving Jakavi. In patients with MF and PV treated with Jakavi in clinical studies, the rates of thromboembolic events were similar in Jakavi and control-treated patients.</p><p>Prior to initiating or continuing therapy with Jakavi, the benefits and risks for the individual patient should be considered, particularly in patients with cardiovascular risk factors (see also section 4.4 &ldquo;Major adverse cardiovascular events (MACE)&rdquo;).</p><p>Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.</p><p>&nbsp;</p><p><u>Second primary malignancies</u></p><p>In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in rheumatoid arthritis patients 50 years of age and older with at least one additional cardiovascular risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC) was observed with tofacitinib compared to TNF inhibitors.</p><p>Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including Jakavi.</p><p>Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib. Most of the MF and PV patients had histories of extended treatment with hydroxyurea and prior NMSC or pre-malignant skin lesions. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>The starting dose of Jakavi should be reduced in patients with severe renal impairment. For patients with end‑stage renal disease on haemodialysis the starting dose should be based on platelet counts for MF patients, while the recommended starting dose is a single dose of 10&nbsp;mg for PV patients (see section&nbsp;4.2). Subsequent doses (single dose of 20&nbsp;mg or two doses of 10&nbsp;mg given 12&nbsp;hours apart in MF patients; single dose of 10&nbsp;mg or two doses of 5&nbsp;mg given 12&nbsp;hours apart in PV patients) should be administered only on haemodialysis days following each dialysis session. Additional dose modifications should be made with careful monitoring of safety and efficacy (see sections&nbsp;4.2 and 5.2).</p><p><em>Hepatic impairment</em></p><p>The starting dose of Jakavi should be reduced by approximately 50% in MF and PV patients with hepatic impairment. Further dose modifications should be based on the safety and efficacy of the medicinal product. In GvHD patients with hepatic impairment not related to GvHD, the starting dose of Jakavi should be reduced by approximately 50% (see sections&nbsp;4.2 and 5.2).</p><p><u>Interactions</u></p><p>If Jakavi is to be co‑administered with strong CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole), the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (for monitoring frequency see sections&nbsp;4.2 and 4.5).</p><p>The concomitant use of cytoreductive therapies with Jakavi was associated with manageable cytopenias (see section&nbsp;4.2 for dose modifications during cytopenias).</p><p>&nbsp;</p><p><u>Withdrawal effects</u></p><p>Following interruption or discontinuation of Jakavi, symptoms of MF may return over a period of approximately one week. There have been cases of patients discontinuing Jakavi who experienced severe adverse events, particularly in the presence of acute intercurrent illness. It has not been established whether abrupt discontinuation of Jakavi contributed to these events. Unless abrupt discontinuation is required, gradual tapering of the dose of Jakavi may be considered, although the utility of the tapering is unproven.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Jakavi contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p></td></tr></tbody></table><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Interaction studies have only been performed in adults.</p><p>Ruxolitinib is eliminated through metabolism catalysed by CYP3A4 and CYP2C9. Thus, medicinal products inhibiting these enzymes can give rise to increased ruxolitinib exposure.</p><p>&nbsp;</p><p><u>Interactions resulting in dose reduction of ruxolitinib</u></p><p><em><u>CYP3A4 inhibitors</u></em></p><p><em>Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)</em></p><p>In healthy subjects co‑administration of ruxolitinib (10&nbsp;mg single dose) with a strong CYP3A4 inhibitor, ketoconazole, resulted in ruxolitinib C<sub>max</sub> and AUC that were higher by 33% and 91%, respectively, than with ruxolitinib alone. The half‑life was prolonged from 3.7 to 6.0&nbsp;hours with concurrent ketoconazole administration.</p><p>When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily.</p><p>Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Dual CYP2C9 and CYP3A4 inhibitors</em></p><p>In healthy subjects co‑administration of ruxolitinib (10&nbsp;mg single dose) with a dual CYP2C9 and CYP3A4 inhibitor, fluconazole, resulted in ruxolitinib C<sub>max</sub> and AUC that were higher by 47% and 232%, respectively, than with ruxolitinib alone.</p><p>50% dose reduction should be considered when using medicinal products which are dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole). Avoid the concomitant use of ruxolitinib with fluconazole doses greater than 200&nbsp;mg daily.</p><p>&nbsp;</p><p><u>Enzyme inducers</u></p><p><em><u>CYP3A4 inducers (such as, but not limited to, avasimibe, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin (rifampicin), St.John&rsquo;s wort (Hypericum perforatum))</u></em></p><p>Patients should be closely monitored and the dose titrated based on safety and efficacy (see section&nbsp;4.2).</p><p>In healthy subjects given ruxolitinib (50&nbsp;mg single dose) following the potent CYP3A4 inducer rifampicin (600&nbsp;mg daily dose for 10&nbsp;days), ruxolitinib AUC was 70% lower than after administration of ruxolitinib alone. The exposure of ruxolitinib active metabolites was unchanged. Overall, the ruxolitinib pharmacodynamic activity was similar, suggesting the CYP3A4 induction resulted in minimal effect on the pharmacodynamics. However, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near E<sub>max</sub>. It is possible that in the individual patient, an increase of the ruxolitinib dose is needed when initiating treatment with a strong enzyme inducer.</p><p>&nbsp;</p><p><u>Other interactions to be considered affecting ruxolitinib</u></p><p><em><u>Mild or moderate CYP3A4 inhibitors (such as, but not limited to, ciprofloxacin, erythromycin, amprenavir, atazanavir, diltiazem, cimetidine)</u></em></p><p>In healthy subjects co‑administration of ruxolitinib (10&nbsp;mg single dose) with erythromycin 500&nbsp;mg twice daily for four days resulted in ruxolitinib C<sub>max </sub>and AUC that were higher by 8% and 27%, respectively, than with ruxolitinib alone.</p><p>No dose adjustment is recommended when ruxolitinib is co‑administered with mild or moderate CYP3A4 inhibitors (e.g. erythromycin). However, patients should be closely monitored for cytopenias when initiating therapy with a moderate CYP3A4 inhibitor.</p><p>&nbsp;</p><p><u>Effects of ruxolitinib on other medicinal products</u></p><p><em><u>Substances transported by P‑glycoprotein or other transporters</u></em></p><p>Ruxolitinib may inhibit P‑glycoprotein and breast cancer resistance protein (BCRP) in the intestine. This may result in increased sytemic exposure of substrates of these transporters, such as dabigatran etexilate, ciclosporin, rosuvastatin and potentially digoxin. Therapeutic drug monitoring (TDM) or clinical monitoring of the affected substance is advised.</p><p>It is possible that the potential inhibition of P‑gp and BCRP in the intestine can be minimised if the time between administrations is kept apart as long as possible.</p><p>A study in healthy subjects indicated that ruxolitinib did not inhibit the metabolism of the oral CYP3A4 substrate midazolam. Therefore, no increase in exposure of CYP3A4 substrates is anticipated when combining them with ruxolitinib. Another study in healthy subjects indicated that ruxolitinib does not affect the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel. Therefore, it is not anticipated that the contraceptive efficacy of this combination will be compromised by co-administration of ruxolitinib.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u>Pregnancy</u></p><p>There are no data from the use of Jakavi in pregnant women.</p><p>Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic. Teratogenicity was not observed in rats or rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans (see section&nbsp;5.3). The potential risk for humans is unknown. As a precautionary measure, the use of Jakavi during pregnancy is contraindicated (see section&nbsp;4.3).</p><p><u>Women of childbearing potential/Contraception</u></p><p>Women of child‑bearing potential should use effective contraception during the treatment with Jakavi. In case pregnancy should occur during treatment with Jakavi, a risk/benefit evaluation must be carried out on an individual basis with careful counselling regarding potential risks to the foetus (see section&nbsp;5.3).</p><p><u>Breast‑feeding</u></p><p>Jakavi must not be used during breast‑feeding (see section&nbsp;4.3) and breast‑feeding should therefore be discontinued when treatment is started. It is unknown whether ruxolitinib and/or its metabolites are excreted in human milk. A risk to the breast‑fed child cannot be excluded. Available pharmacodynamic/toxicological data in animals have shown excretion of ruxolitinib and its metabolites in milk (see section&nbsp;5.3).</p><p><u>Fertility</u></p><p>There are no human data on the effect of ruxolitinib on fertility. In animal studies, no effect on fertility was observed.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Jakavi has no or negligible sedating effect. However, patients who experience dizziness after the intake of Jakavi should refrain from driving or using machines.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u>Summary of the safety profile</u></p><p><em><u>Myelofibrosis</u></em></p><p>The most frequently reported adverse drug reactions were thrombocytopenia and anaemia.</p><p>&nbsp;</p><p>Haematological adverse drug reactions (any Common Terminology Criteria for Adverse Events [CTCAE] grade) included anaemia (83.8%), thrombocytopenia (80.5%) and neutropenia (20.8%).</p><p>&nbsp;</p><p>Anaemia, thrombocytopenia and neutropenia are dose‑related effects.</p><p>&nbsp;</p><p>The three most frequent non‑haematological adverse drug reactions were bruising (33.3%), other bleeding (including epistaxis, post‑procedural haemorrhage and haematuria) (24.3%) and dizziness (21.9%).</p><p>&nbsp;</p><p>The three most frequent non‑haematological laboratory abnormalities identified as adverse reactions were increased alanine aminotransferase (40.7%), increased aspartate aminotransferase (31.5%) and hypertriglyceridaemia (25.2%). In phase&nbsp;3 clinical studies in MF, neither CTCAE grade&nbsp;3 or 4 hypertriglyceridaemia or increased aspartate aminotransferase, nor CTCAE grade&nbsp;4 increased alanine aminotransferase or hypercholesterolaemia were observed.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.</p><p>&nbsp;</p><p><em><u>Polycythaemia vera</u></em></p><p>The most frequently reported adverse drug reactions were anaemia and increased alanine aminotransferase.</p><p>Haematological adverse reactions (any CTCAE grade) included anaemia (61.8%), thrombocytopenia (25.0%) and neutropenia (5.3%). Anaemia and thrombocytopenia CTCAE grade&nbsp;3 or 4 were reported in 2.9% and 2.6% of the patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse reactions were weight gain (20.3%), dizziness (19.4%) and headache (17.9%).</p><p>The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) identified as adverse reactions were increased alanine aminotransferase (45.3%), increased aspartate aminotransferase (42.6%), and hypercholesterolaemia (34.7%). No CTCAE grade&nbsp;4 increased alanine aminotransferase or hypercholesterolaemia, and one CTCAE grade&nbsp;4 increased aspartate aminotransferase were observed.</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.</p><p><em><u>Acute GvHD</u></em></p><p>The most frequently reported overall adverse drug reactions were thrombocytopenia, anaemia and neutropenia.</p><p>&nbsp;</p><p>Haematological laboratory abnormalities identified as adverse drug reactions included thrombocytopenia (85.2%), anaemia (75.0%) and neutropenia (65.1%). Grade&nbsp;3 anaemia was reported in 47.7% of patients (grade&nbsp;4 not applicable per CTCAE v4.03). Grade&nbsp;3 and 4 thrombocytopenia were reported in 31.3% and 47.7% of patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse drug reactions were cytomegalovirus (CMV) infection (32.3%), sepsis (25.4%) and urinary tract infections (17.9%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities identified as adverse drug reactions were increased alanine aminotransferase (54.9%), increased aspartate aminotransferase (52.3%) and hypercholesterolaemia (49.2%). The majority were of grade&nbsp;1 and 2.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients.</p><p>&nbsp;</p><p><em><u>Chronic GvHD</u></em></p><p>The most frequently reported overall adverse drug reactions were anaemia, hypercholesterolemia and increased aspartate aminotransferase.</p><p>&nbsp;</p><p>Haematological laboratory abnormalities identified as adverse drug reactions included anaemia (68.6%), thrombocytopenia (34.4%) and neutropenia (36.2%). Grade&nbsp;3 anaemia was reported in 14.8% of patients (grade&nbsp;4 not applicable per CTCAE v4.03). Grade&nbsp;3 and 4 neutropenia were reported in 9.5% and 6.7% of patients, respectively.</p><p>&nbsp;</p><p>The three most frequent non-haematological adverse drug reactions were hypertension (15.0%), headache (10.2%) and urinary tract infections (9.3%).</p><p>&nbsp;</p><p>The three most frequent non-haematological laboratory abnormalities identified as adverse drug reactions were hypercholesterolaemia (52.3%), increased aspartate aminotransferase (52.2%) and increased alanine aminotransferase (43.1%). The majority were grade&nbsp;1 and 2.</p><p>&nbsp;</p><p>Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients.</p><p><em>&nbsp;</em></p><p><u>Tabulated list of adverse drug reactions from clinical studies</u></p><p>&nbsp;</p><p>The safety of Jakavi in MF patients was evaluated using the long-term follow-up data from two phase&nbsp;3 studies (COMFORT‑I and COMFORT‑II) including data from patients initially randomised to ruxolitinib (n=301) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for MF patients are based was 30.5&nbsp;months (range 0.3 to 68.1&nbsp;months).</p><p>&nbsp;</p><p>The safety of Jakavi in PV patients was evaluated using the long-term follow-up data from two phase&nbsp;3 studies (RESPONSE, RESPONSE&nbsp;2) including data from patients initially randomised to ruxolitinib (n=184) and patients who received ruxolitinib after crossing over from control treatments (n=156). The median exposure upon which the adverse drug reaction frequency categories for PV patients are based was 41.7&nbsp;months (range 0.03 to 59.7&nbsp;months).</p><p>&nbsp;</p><p>The safety of Jakavi in acute GvHD patients was evaluated in the phase&nbsp;3 study REACH2, including data from patients initially randomised to Jakavi (n=152) and patients who received Jakavi after crossing over from the best available therapy (BAT) arm (n=49). The median exposure upon which the adverse drug reaction frequency categories were based was 8.9&nbsp;weeks (range 0.3 to 66.1&nbsp;weeks).</p><p>&nbsp;</p><p>The safety of Jakavi in chronic GvHD patients was evaluated in the phase&nbsp;3 study REACH3, including data from patients initially randomised to Jakavi (n=165) and patients who received Jakavi after crossing over from BAT (n=61). The median exposure upon which the adverse drug reaction frequency categories were based was 41.4&nbsp;weeks (range 0.7 to 127.3&nbsp;weeks).</p><p>&nbsp;</p><p>In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade&nbsp;1=mild, grade&nbsp;2=moderate, grade&nbsp;3=severe, grade&nbsp;4=life‑threatening or disabling, grade&nbsp;5=death.</p><p>&nbsp;</p><p>Adverse drug reactions from clinical studies in MF and PV (Table&nbsp;4) and in acute and chronic GvHD (Table&nbsp;5) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency category of adverse drug reactions reported in the phase&nbsp;3 studies in MF and PV</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse drug reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category for MF patients</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category for PV patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Urinary tract infections<sup>d</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Herpes zoster<sup>d</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Pneumonia</p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Sepsis</p></td><td><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Tuberculosis</p></td><td><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known<sup>e</sup></p></td></tr><tr><td><p>HBV reactivation</p></td><td><p>Not known<sup>e</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Herpes simplex virus reactivation and/or dissemination</p></td><td><p>Not known<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Not known<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders<sup>a,d</sup></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CTCAE<sup>c</sup> grade&nbsp;4</p><p>(&lt;6.5g/dl)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>CTCAE<sup>c</sup> grade&nbsp;3</p><p>(&lt;8.0 &ndash; 6.5g/dl)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>CTCAE<sup>c</sup> grade&nbsp;4</p><p>(&lt;25,000/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>CTCAE<sup>c</sup> grade&nbsp;3</p><p>(50,000 &ndash; 25,000/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>CTCAE<sup>c</sup> grade&nbsp;4</p><p>(&lt;500/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>CTCAE<sup>c</sup> grade&nbsp;3</p><p>(&lt;1,000 &ndash; 500/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>a,b</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bleeding (any bleeding including intracranial, and gastrointestinal bleeding, bruising and other bleeding)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Bruising</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal bleeding</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial bleeding</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Other bleeding (including epistaxis, post‑procedural haemorrhage and haematuria)</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>a</sup></p><p>any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Hypertriglyceridaemia<sup>a</sup></p><p>any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Weight gain</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Elevated lipase, any CTCAE<sup>c</sup> grade</p></td><td><p>Very common</p></td><td><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>CTCAE<sup>c</sup> grade&nbsp;3</p><p>(&gt; 5x &ndash; 20 x ULN)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Increased aspartate aminotransferase<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Any CTCAE<sup>c</sup> grade</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Hypertension</p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Frequency is based on new or worsened laboratory abnormalities compared to baseline.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Pancytopenia is defined as haemoglobin level &lt;100&nbsp;g/l, platelet count &lt;100x10<sup>9</sup>/l, and neutrophil count &lt;1.5x10<sup>9</sup>/l (or low white blood cell count of grade&nbsp;2 if neutrophil count is missing), simultaneously in the same lab assessment</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Common Terminology Criteria for Adverse Events (CTCAE) version&nbsp;3.0; grade&nbsp;1 = mild, grade&nbsp;2 = moderate, grade&nbsp;3 = severe, grade&nbsp;4 = life‑threatening</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>These ADRs are discussed in the text.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADR derived from post-marketing experience</p></td></tr></tbody></table><p>&nbsp;</p><p>Upon discontinuation, MF patients may experience a return of MF symptoms such as fatigue, bone pain, fever, pruritus, night sweats, symptomatic splenomegaly and weight loss. In clinical studies in MF the total symptom score for MF symptoms gradually returned to baseline value within 7&nbsp;days after dose discontinuation (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency category of adverse drug reactions reported in the phase&nbsp;3 studies in GvHD</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:107%"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Acute GvHD (REACH2)</strong></p></td><td><p><strong>Chronic GvHD (REACH3)</strong></p></td></tr><tr><td><p><strong>Adverse drug reaction</strong></p></td><td><p><strong>Frequency category</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td colspan="3"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>CMV infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE<sup>3</sup> grade &ge;3</p></td><td><p>Very common</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td><p>Very common</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td><p>Very common</p></td><td><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infections</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td><p>Common</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>BK virus infections</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p></td><td><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia<sup>1,2</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Weight gain</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>N/A<sup>5</sup></p></td></tr><tr><td colspan="3"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased lipase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Increased amylase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade &ge;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>N/A<sup>5</sup></p></td></tr><tr><td colspan="3"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased alanine aminotransferase<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Increased aspartate aminotransferase<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>N/A<sup>5</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased blood creatine phosphokinase<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased blood creatinine<sup>1</sup></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTCAE grade&nbsp;4</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>N/A<sup>5</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Frequency is based on new or worsened laboratory abnormalities compared to baseline.</p><p><sup>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Pancytopenia is defined as haemoglobin level &lt;100&nbsp;g/l, platelet count &lt;100&nbsp;x&nbsp;10<sup>9</sup>/l, and neutrophil count &lt;1.5&nbsp;x&nbsp;10<sup>9</sup>/l (or low white blood cell count of grade&nbsp;2 if neutrophil count is missing), simultaneously in the same laboratory assessment.</p><p><sup>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>CTCAE Version 4.03.</p><p><sup>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Grade&nbsp;&ge;3 sepsis includes 20 (10%) grade&nbsp;5 events.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not applicable: no cases reported</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse drug reactions</u></p><p>&nbsp;</p><p><em><u>Anaemia</u></em></p><p>In phase&nbsp;3 clinical studies in MF, median time to onset of first CTCAE grade&nbsp;2 or higher anaemia was 1.5&nbsp;months. One patient (0.3%) discontinued treatment because of anaemia.</p><p>&nbsp;</p><p>In patients receiving ruxolitinib mean decreases in haemoglobin reached a nadir of approximately 10&nbsp;g/litre below baseline after 8 to 12&nbsp;weeks of therapy and then gradually recovered to reach a new steady state that was approximately 5&nbsp;g/litre below baseline. This pattern was observed in patients regardless of whether they had received transfusion during therapy.</p><p>&nbsp;</p><p>In the randomised, placebo‑controlled study COMFORT‑I 60.6% of Jakavi‑treated MF patients and 37.7% of placebo‑treated MF patients received red blood cell transfusions during randomised treatment. In the COMFORT‑II study the rate of packed red blood cell transfusions was 53.4% in the Jakavi arm and 41.1% in the best available therapy arm.</p><p>&nbsp;</p><p>In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (40.8% versus 82.4%). In the PV population, the CTCAE grade&nbsp;3 and 4 events were reported in 2.7%, while in the MF patients the frequency was 42.56%.</p><p>&nbsp;</p><p>In the phase&nbsp;3 acute and chronic GvHD studies, anaemia CTCAE grade&nbsp;3 was reported in 47.7% and 14.8% of patients, respectively.</p><p>&nbsp;</p><p><em><u>Thrombocytopenia</u></em></p><p>In the phase&nbsp;3 clinical studies in MF, in patients who developed grade&nbsp;3 or 4 thrombocytopenia, the median time to onset was approximately 8&nbsp;weeks. Thrombocytopenia was generally reversible with dose reduction or dose interruption. The median time to recovery of platelet counts above 50,000/mm<sup>3</sup> was 14&nbsp;days. During the randomised period, platelet transfusions were administered to 4.7% of patients receiving ruxolitinib and to 4.0% of patients receiving control regimens. Discontinuation of treatment because of thrombocytopenia occurred in 0.7% of patients receiving ruxolitinib and 0.9% of patients receiving control regimens. Patients with a platelet count of 100,000/mm<sup>3</sup> to 200,000/mm<sup>3</sup> before starting ruxolitinib had a higher frequency of grade&nbsp;3 or 4 thrombocytopenia compared to patients with platelet count &gt;200,000/mm<sup>3</sup> (64.2% versus 38.5%).</p><p>&nbsp;</p><p>In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (16.8%) patients compared to MF (69.8%) patients. The frequency of severe (i.e. CTCAE grade&nbsp;3 and 4) thrombocytopenia was lower in PV (2.7%) than in MF (11.6%) patients.</p><p>&nbsp;</p><p>In the phase&nbsp;3 acute GvHD study, grade&nbsp;3 and 4 thrombocytopenia was observed in 31.3% and 47.7% of patients, respectively. In the phase&nbsp;3 chronic GvHD study, grade&nbsp;3 and 4 thrombocytopenia was lower (5.9% and 10.7%) than in acute GvHD.</p><p>&nbsp;</p><p><em><u>Neutropenia</u></em></p><p>In the phase&nbsp;3 clinical studies in MF, in patients who developed grade&nbsp;3 or 4 neutropenia, the median time to onset was 12&nbsp;weeks. During the randomised period, dose holding or reductions due to neutropenia were reported in 1.0% of patients, and 0.3% of patients discontinued treatment because of neutropenia.</p><p>&nbsp;</p><p>In the randomised period of the phase&nbsp;3 studies in PV patients, neutropenia was reported in 1.6% of patients exposed to ruxolitinib compared to 7% in reference treatments. In the ruxolitinib arm one patient developed CTCAE grade&nbsp;4 neutropenia. An extended follow-up of patients treated with ruxolitinib showed 2&nbsp;patients reporting CTCAE grade&nbsp;4 neutropenia.</p><p>&nbsp;</p><p>In the phase&nbsp;3 acute GvHD study, grade&nbsp;3 and 4 neutropenia was observed in 17.9% and 20.6% of patients, respectively. In the phase&nbsp;3 chronic GvHD study grade&nbsp;3 and 4 neutropenia was lower (9.5% and 6.7%) than in acute GvHD.</p><p>&nbsp;</p><p><em><u>Bleeding</u></em></p><p>In the phase&nbsp;3 pivotal studies in MF bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 32.6% of patients exposed to ruxolitinib and 23.2% of patients exposed to the reference treatments (placebo or best available therapy). The frequency of grade&nbsp;3‑4 events was similar for patients treated with ruxolitinib or reference treatments (4.7% versus 3.1%). Most of the patients with bleeding events during the treatment reported bruising (65.3%). Bruising events were more frequently reported in patients taking ruxolitinib compared with the reference treatments (21.3% versus 11.6%). Intracranial bleeding was reported in 1% of patients exposed to ruxolitinib and 0.9% exposed to reference treatments. Gastrointestinal bleeding was reported in 5.0% of patients exposed to ruxolitinib compared to 3.1% exposed to reference treatments. Other bleeding events (including events such as epistaxis, post‑procedural haemorrhage and haematuria) were reported in 13.3% of patients treated with ruxolitinib and 10.3% treated with reference treatments.</p><p>&nbsp;</p><p>During the long-term follow-up of phase&nbsp;3 clinical studies in MF, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (33.3%). Intracranial and gastrointestinal bleeding events were reported in 1.3% and 10.1% of patients respectively.</p><p>&nbsp;</p><p>In the comparative period of phase&nbsp;3 studies in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 16.8% of patients treated with ruxolitinib, 15.3% of patients receiving best available therapy in RESPONSE study and 12.0% of patients receiving best available therapy in RESPONSE&nbsp;2 study. Bruising was reported in 10.3% of patients treated with ruxolitinib, 8.1% of patients receiving best available therapy in RESPONSE study and 2.7% of patients receiving best available therapy in RESPONSE&nbsp;2 study. No intracranial bleeding or gastrointestinal haemorrhage events were reported in patients receiving ruxolitinib. One patient treated with ruxolitinib experienced a grade&nbsp;3 bleeding event (post‑procedural bleeding); no grade&nbsp;4 bleeding was reported. Other bleeding events (including events such as epistaxis, post‑procedural haemorrhage, gingival bleeding) were reported in 8.7% of patients treated with ruxolitinib, 6.3% of patients treated with best available therapy in RESPONSE study and 6.7% of patients treated with best available therapy in RESPONSE&nbsp;2 study.</p><p>&nbsp;</p><p>During the long-term follow-up of phase&nbsp;3 studies in PV, the cumulative frequency of bleeding events increased proportionally to the increase in the follow-up time. Bruising events were the most frequently reported bleeding events (17.4%). Intracranial and gastrointestinal bleeding events were reported in 0.3% and 3.5% of patients respectively.</p><p>&nbsp;</p><p>In the comparative period of the phase&nbsp;3 acute GvHD study, bleeding events were reported in 25.0% and 22.0% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (5.9% in ruxolitinib vs. 6.7% in BAT arm), gastrointestinal events (9.2% vs. 6.7%) and other haemorrhage events (13.2% vs. 10.7%). Intracranial bleeding events were reported in 0.7% of patients in the BAT arm and in no patients in the ruxolitinib arm.</p><p>&nbsp;</p><p>In the comparative period of the phase&nbsp;3 chronic GvHD study, bleeding events were reported in 11.5% and 14.6% of patients in the ruxolitinib and BAT arms respectively. The sub-groups of bleeding events were generally similar between treatment arms: bruising events (4.2% in ruxolitinib vs. 2.5% in BAT arm), gastrointestinal events (1.2% vs. 3.2%) and other haemorrhage events (6.7% vs. 10.1%). No intracranial bleeding events were reported in either treatment arm.</p><p>&nbsp;</p><p><em><u>Infections</u></em></p><p>In the phase&nbsp;3 pivotal studies in MF, grade&nbsp;3 or 4 urinary tract infection was reported in 1.0% of patients, herpes zoster in 4.3% and tuberculosis in 1.0%. In phase&nbsp;3 clinical studies sepsis was reported in 3.0% of patients. An extended follow-up of patients treated with ruxolitinib showed no trends towards an increase in the rate of sepsis over time.</p><p>&nbsp;</p><p>In the randomised period of the phase&nbsp;3 studies in PV patients, one (0.5%) CTCAE grade&nbsp;3 and no grade&nbsp;4 urinary tract infection was reported. The rate of herpes zoster was similar in PV (4.3%) patients and MF (4.0%) patients. There was one report of CTCAE grade&nbsp;3 post-herpetic neuralgia amongst the PV patients. Pneumonia was reported in 0.5% of patients treated with ruxolitinib compared to 1.6% of patients in reference treatments. No patients in the ruxolitinib arm reported sepsis or tuberculosis.</p><p>&nbsp;</p><p>During long-term follow-up of phase&nbsp;3 studies in PV, frequently reported infections were urinary tract infections (11.8%), herpes zoster (14.7%) and pneumonia (7.1%). Sepsis was reported in 0.6% of patients. No patients reported tuberculosis in long-term follow-up.</p><p>&nbsp;</p><p>In the phase&nbsp;3 acute GvHD study, during the <em>comparative period</em>, urinary tract infections were reported in 9.9% (grade &ge;3, 3.3%) of patients in the ruxolitinib arm compared to 10.7% (grade &ge;3, 6.0%) in the BAT arm. CMV infections were reported in 28.3% (grade &ge;3, 9.3%) of patients in the ruxolitinib arm compared to 24.0% (grade &ge;3, 10.0%) in the BAT arm. Sepsis events were reported in 12.5% (grade &ge;3, 11.1%) of patients in the ruxolitinib arm compared to 8.7% (grade &ge;3, 6.0%) in the BAT arm. BK virus infection was reported only in the ruxolitinib arm in 3&nbsp;patients with one grade&nbsp;3 event. During <em>extended follow‑up</em> of patients treated with ruxolitinib, urinary tract infections were reported in 17.9% (grade&nbsp;&ge;3, 6.5%) of patients and CMV infections were reported in 32.3% (grade&nbsp;&ge;3, 11.4%) of patients. CMV infection with organ involvement was seen in very few patients; CMV colitis, CMV enteritis and CMV gastrointestinal infection of any grade were reported in four, two and one patients, respectively. Sepsis events, including septic shock, of any grade were reported in 25.4% (grade&nbsp;&ge;3, 21.9%) of patients.</p><p>&nbsp;</p><p>In the phase&nbsp;3 chronic GvHD study, during the <em>comparative period</em>, urinary tract infections were reported in 8.5% (grade &ge;3, 1.2%) of patients in the ruxolitinib arm compared to 6.3% (grade&nbsp;&ge;3, 1.3%) in the BAT arm. BK virus infection was reported in 5.5% (grade&nbsp;&ge;3, 0.6%) of patients in the ruxolitinib arm compared to 1.3% in the BAT arm. CMV infections were reported in 9.1% (grade&nbsp;&ge;3, 1.8%) of patients in the ruxolitinib arm compared to 10.8% (grade&nbsp;&ge;3, 1.9%) in the BAT arm. Sepsis events were reported in 2.4% (grade&nbsp;&ge;3, 2.4%) of patients in the ruxolitinib arm compared to 6.3% (grade&nbsp;&ge;3, 5.7%) in the BAT arm. During <em>extended follow‑up</em> of patients treated with ruxolitinib, urinary tract infections and BK virus infections were reported in 9.3% (grade&nbsp;&ge;3, 1.3%) and 4.9% (grade&nbsp;&ge;3, 0.4%) of patients, respectively. CMV infections and sepsis events were reported in 8.8% (grade&nbsp;&ge;3, 1.3%) and 3.5% (grade&nbsp;&ge;3, 3.5%) of patients, respectively.</p><p>&nbsp;</p><p><em><u>Elevated lipase</u></em></p><p>In the randomised period of the RESPONSE study, the worsening of lipase values was higher in the ruxolitinib arm compared to the control arm, mainly due to the differences among grade&nbsp;1 elevations (18.2% vs 8.1%). Grade &ge;2 elevations were similar between treatment arms. In RESPONSE&nbsp;2, the frequencies were comparable between the ruxolitinib and the control arm (10.8% vs 8%). During long-term follow-up of phase&nbsp;3 PV studies, 7.4% and 0.9% of patients reported grade&nbsp;3 and grade&nbsp;4 elevation of lipase values. No concurrent signs and symptoms of pancreatitis with elevated lipase values were reported in these patients.</p><p>&nbsp;</p><p>In phase&nbsp;3 studies in MF, high lipase values were reported in 18.7% and 19.3% of patients in the ruxolitinib arms compared to 16.6% and 14.0% in the control arms in COMFORT‑I and COMFORT‑II studies, respectively. In patients with elevated lipase values, no concurrent signs and symptoms of pancreatitis were reported.</p><p>&nbsp;</p><p>In the <em>comparative period</em> of the phase&nbsp;3 acute GvHD study, new or worsened lipase values were reported in 19.7% of patients in the ruxolitinib arm compared to 12.5% in the BAT arm; corresponding grade&nbsp;3 (3.1% vs 5.1%) and grade&nbsp;4 (0% vs 0.8%) increases were similar. During <em>extended follow‑up</em> of patients treated with ruxolitinib, increased lipase values were reported in 32.2% of patients; grade&nbsp;3 and 4 were reported in 8.7% and 2.2% of patients respectively.</p><p>&nbsp;</p><p>In the <em>comparative period</em> of the phase&nbsp;3 chronic GvHD study, new or worsened lipase values were reported in 32.1% of patients in the ruxolitinib arm compared to 23.5% in the BAT arm; corresponding grade&nbsp;3 (10.6% vs 6.2%) and grade&nbsp;4 (0.6% vs 0%) increases were similar. During <em>extended follow‑up</em> of patients treated with ruxolitinib, increased lipase values were reported in 35.9% of patients; grade&nbsp;3 and 4 were observed in 9.5% and 0.4% of patients, respectively.</p><p>&nbsp;</p><p><em><u>Increased systolic blood pressure</u></em></p><p>In the phase&nbsp;3 pivotal clinical studies in MF an increase in systolic blood pressure of 20&nbsp;mmHg or more from baseline was recorded in 31.5% of patients on at least one visit compared with 19.5% of the control‑treated patients. In COMFORT‑I (MF patients) the mean increase from baseline in systolic BP was 0‑2&nbsp;mmHg on ruxolitinib versus a decrease of 2‑5&nbsp;mmHg in the placebo arm. In COMFORT‑II mean values showed little difference between the ruxolitinib‑treated and the control‑treated MF patients.</p><p>&nbsp;</p><p>In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65&nbsp;mmHg in the ruxolitinib arm versus a decrease of 2&nbsp;mmHg in the BAT arm.</p><p><u>&nbsp;</u></p><p><em>Paediatric patients</em></p><p>A total of 20&nbsp;patients aged 12 to &lt;18&nbsp;years with GvHD were analysed for safety: 9&nbsp;patients (5 in the ruxolitinib arm and 4 in the BAT arm) in the study REACH2 and 11&nbsp;patients (4 in the ruxolitinib arm and 7 in the BAT arm) in the study REACH3. Based on the similar exposure observed in adolescents and adults, the safety of ruxolitinib at the recommended dose of 10&nbsp;mg twice daily is similar in frequency and severity.</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>A total of 29&nbsp;patients in study REACH2 and 25&nbsp;patients in REACH3 aged &gt;65&nbsp;years and treated with ruxolitinib were analysed for safety. Overall, no new safety concerns were identified and the safety profile in patients &gt;65&nbsp;years old is generally consistent with that of patients aged 18-65&nbsp;years old.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To report any complaint(s):</strong> complaints.ksa@novartis.com</p></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>There is no known antidote for overdoses with Jakavi. Single doses up to 200&nbsp;mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given.</p><p>&nbsp;</p><p>Haemodialysis is not expected to enhance the elimination of ruxolitinib.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EJ01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC<sub>50</sub> values of 3.3&nbsp;nM and 2.8&nbsp;nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.</p><p>MF and PV are myeloproliferative neoplasms known to be associated with dysregulated JAK1 and JAK2 signalling. The basis for the dysregulation is believed to include high levels of circulating cytokines that activate the JAK‑STAT pathway, gain‑of‑function mutations such as JAK2V617F, and silencing of negative regulatory mechanisms. MF patients exhibit dysregulated JAK signalling regardless of JAK2V617F mutation status. Activating mutations in JAK2 (V617F or exon 12) are found in &gt;95% of PV patients.</p><p>Ruxolitinib inhibits JAK‑STAT signalling and cell proliferation of cytokine‑dependent cellular models of haematological malignancies, as well as of Ba/F3 cells rendered cytokine‑independent by expressing the JAK2V617F mutated protein, with IC<sub>50</sub> ranging from 80‑320&nbsp;nM.</p><p>JAK-STAT signalling pathways play a role in regulating the development, proliferation, and activation of several immune cell types important for GvHD pathogenesis.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Ruxolitinib inhibits cytokine‑induced STAT3 phosphorylation in whole blood from healthy subjects, MF patients and PV patients. Ruxolitinib resulted in maximal inhibition of STAT3 phosphorylation 2&nbsp;hours after dosing which returned to near baseline by 8&nbsp;hours in both healthy subjects and MF patients, indicating no accumulation of either parent or active metabolites.</p><p>&nbsp;</p><p>Baseline elevations in inflammatory markers associated with constitutional symptoms such as TNF&alpha;, IL‑6 and CRP in subjects with MF were decreased following treatment with ruxolitinib. MF patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time. Similarly, patients with PV also presented with baseline elevations in inflammatory markers and these markers were decreased following treatment with ruxolitinib.</p><p>&nbsp;</p><p>In a thorough QT study in healthy subjects, there was no indication of a QT/QTc prolonging effect of ruxolitinib in single doses up to a supratherapeutic dose of 200&nbsp;mg, indicating that ruxolitinib has no effect on cardiac repolarisation.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Myelofibrosis</u></em></p><p>Two randomised phase&nbsp;3 studies (COMFORT‑I and COMFORT‑II) were conducted in patients with MF (primary MF, post‑polycythaemia vera MF or post‑essential thrombocythaemia MF). In both studies, patients had palpable splenomegaly at least 5&nbsp;cm below the costal margin and risk category of intermediate‑2 or high risk based on the International Working Group (IWG) Consensus Criteria. The starting dose of Jakavi was based on platelet count. Patients with platelet counts &le;100,000/mm<sup>3</sup> were not eligible for enrolment in COMFORT studies but 69&nbsp;patients were enrolled in the EXPAND study, a Phase&nbsp;Ib, open label, dose-finding study in patients with MF (primary MF, post‑polycythaemia vera MF or post‑essential thrombocythaemia MF) and baseline platelet counts &ge;50,000 and &lt;100,000/mm<sup>3</sup>.</p><p>&nbsp;</p><p>COMFORT‑I was a double‑blind, randomised, placebo‑controlled study in 309&nbsp;patients who were refractory to or were not candidates for available therapy. The primary efficacy endpoint was proportion of subjects achieving &ge;35% reduction from baseline in spleen volume at week&nbsp;24 as measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).</p><p>&nbsp;</p><p>Secondary endpoints included duration of maintenance of a &ge;35% reduction from baseline in spleen volume, proportion of patients who had &ge;50% reduction in total symptom score, changes in total symptom scores from baseline to week&nbsp;24, as measured by the modified MF Symptom Assessment Form (MFSAF) v2.0 diary, and overall survival.</p><p>&nbsp;</p><p>COMFORT‑II was an open‑label, randomised study in 219&nbsp;patients. Patients were randomised 2:1 to ruxolitinib versus best available therapy. In the best available therapy arm, 47% of patients received hydroxyurea and 16% of patients received glucocorticoids. The primary efficacy endpoint was proportion of patients achieving &ge;35% reduction from baseline in spleen volume at week&nbsp;48 as measured by MRI or CT.</p><p>&nbsp;</p><p>Secondary endpoints included proportion of patients achieving a &ge;35% reduction of spleen volume from baseline at week&nbsp;24 and duration of maintenance of a &ge;35% reduction from baseline spleen volume.</p><p>&nbsp;</p><p>In COMFORT‑I and COMFORT‑II, patient baseline demographics and disease characteristics were comparable between the treatment arms.</p><p>&nbsp;</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Percentage of patients with &ge;35% reduction from baseline in spleen volume at week&nbsp;24 in COMFORT‑I and at week&nbsp;48 in COMFORT‑II (ITT)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>COMFORT‑I</p></td><td colspan="2" style="vertical-align:top"><p>COMFORT‑II</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jakavi</p><p>(N=155)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N=153)</p></td><td style="vertical-align:top"><p>Jakavi</p><p>(N=144)</p></td><td style="vertical-align:top"><p>Best available therapy</p><p>(N=72)</p></td></tr><tr><td style="vertical-align:top"><p>Time points</p></td><td colspan="2" style="vertical-align:top"><p>Week&nbsp;24</p></td><td colspan="2" style="vertical-align:top"><p>Week&nbsp;48</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of subjects with spleen volume reduced by &ge;35%</p></td><td style="vertical-align:top"><p>65 (41.9)</p></td><td style="vertical-align:top"><p>1 (0.7)</p></td><td style="vertical-align:top"><p>41 (28.5)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>95% confidence intervals</p></td><td style="vertical-align:top"><p>34.1, 50.1</p></td><td style="vertical-align:top"><p>0, 3.6</p></td><td style="vertical-align:top"><p>21.3, 36.6</p></td><td style="vertical-align:top"><p>0.0, 5.0</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr></tbody></table><p>&nbsp;</p><p>A significantly higher proportion of patients in the Jakavi group achieved &ge;35% reduction from baseline in spleen volume (Table&nbsp;6) regardless of the presence or absence of the JAK2V617F mutation (Table&nbsp;7) or the disease subtype (primary MF, post‑polycythaemia vera MF, post‑essential thrombocythaemia MF).</p><p>&nbsp;</p><p><strong>Table&nbsp;7</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Percentage of patients with &ge;35% reduction from baseline in spleen volume by JAK mutation status (safety set)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:535px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p>COMFORT‑I</p></td><td colspan="4" style="vertical-align:top"><p>COMFORT‑II</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Jakavi</p></td><td colspan="2" style="vertical-align:top"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>Jakavi</p></td><td colspan="2" style="vertical-align:top"><p>Best available therapy</p></td></tr><tr><td style="vertical-align:top"><p>JAK mutation status</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=113)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=40)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=121)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=27)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=110)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=35)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Positive</p><p>(N=49)</p><p>n (%)</p></td><td style="vertical-align:top"><p>Negative</p><p>(N=20)</p><p>n (%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (%) of subjects with spleen volume reduced by &ge;35%</p></td><td style="vertical-align:top"><p>54 (47.8)</p></td><td style="vertical-align:top"><p>11 (27.5)</p></td><td style="vertical-align:top"><p>1<br />(0.8)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>36 (32.7)</p></td><td style="vertical-align:top"><p>5<br />(14.3)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Time point</p></td><td colspan="4" style="vertical-align:top"><p>After 24&nbsp;weeks</p></td><td colspan="4" style="vertical-align:top"><p>After 48&nbsp;weeks</p></td></tr></tbody></table><p>&nbsp;</p><p>The probability of maintaining spleen response (&ge;35% reduction) to Jakavi for at least 24&nbsp;weeks was 89% in COMFORT‑I and 87% in COMFORT‑II; 52% maintained spleen responses for at least 48&nbsp;weeks in COMFORT‑II.</p><p>&nbsp;</p><p>In COMFORT‑I, 45.9% subjects in the Jakavi group achieved a &ge;50% improvement from baseline in the week&nbsp;24 total symptom score (measured using MFSAF diary v2.0), as compared to 5.3% in the placebo group (p&lt;0.0001 using chi-square test). The mean change in the global health status at week&nbsp;24, as measured by EORTC QLQ C30 was +12.3 for Jakavi and ‑3.4 for placebo (p&lt;0.0001).</p><p>&nbsp;</p><p>In COMFORT-I, after a median follow-up of 34.3&nbsp;months, the death rate in patients randomised to the ruxolitinib arm was 27.1% versus 35.1% in patients randomised to placebo; HR 0.687; 95% CI 0.459‑1.029; p=0.0668.</p><p>&nbsp;</p><p>In COMFORT-I, after a median follow&ndash;up of 61.7&nbsp;months, the death rate in patients randomised to the ruxolitinib arm was 44.5% (69 of 155&nbsp;patients) versus 53.2% (82 of 154) in patients randomised to placebo. There was a 31% reduction in the risk of death in the ruxolitinib arm as compared to placebo (HR 0.69; 95% CI 0.50-0.96; p=0.025).</p><p>&nbsp;</p><p>In COMFORT-II, after a median follow‑up of 34.7&nbsp;months, the death rate in patients randomised to ruxolitinib was 19.9% versus 30.1% in patients randomised to best available treatment (BAT); HR 0.48; 95% CI 0.28‑0.85; p=0.009. In both studies, the lower death rates noted in the ruxolitinib arm were predominantly driven by the results obtained in the post polycythaemia vera and post essential thrombocythaemia subgroups.</p><p>&nbsp;</p><p>In COMFORT-II, after a median follow-up of 55.9&nbsp;months, the death rate in patients randomised to the ruxolitinib arm was 40.4% (59 of 146&nbsp;patients) versus 47.9% (35 of 73&nbsp;patients) in patients randomized to best available therapy (BAT). There was a 33% reduction in risk of death in the ruxolitinib arm compared to the BAT arm (HR 0.67; 95% CI 0.44-1.02; p=0.062).</p><p>&nbsp;</p><p><em><u>Polycythaemia vera</u></em></p><p>A randomised, open-label, active-controlled phase&nbsp;3 study (RESPONSE) was conducted in 222&nbsp;patients with PV who were resistant to or intolerant of hydroxyurea defined based on the European LeukemiaNet (ELN) international working group published criteria. 110&nbsp;patients were randomised to the ruxolitinib arm and 112&nbsp;patients to the BAT arm. The starting dose of Jakavi was 10&nbsp;mg twice daily. Doses were then adjusted in individual patients based on tolerability and efficacy with a maximum dose of 25&nbsp;mg twice daily. BAT was selected by the investigator on a patient-by-patient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).</p><p>&nbsp;</p><p>Baseline demographics and disease characteristics were comparable between the two treatments arms. The median age was 60&nbsp;years (range 33 to 90&nbsp;years). Patients in the ruxolitinib arm had PV diagnosis for a median of 8.2&nbsp;years and had previously received hydroxyurea for a median of approximately 3&nbsp;years. Most patients (&gt;80%) had received at least two phlebotomies in the last 24&nbsp;weeks prior to screening. Comparative data regarding long-term survival and incidence of disease complications is missing.</p><p>&nbsp;</p><p>The primary composite endpoint was the proportion of patients achieving both an absence of phlebotomy eligibility (HCT control) and a &ge;35% reduction in spleen volume from baseline at week&nbsp;32. Phlebotomy eligibility was defined as a confirmed HCT of &gt;45%, i.e. at least 3&nbsp;percentage points higher than the HCT obtained at baseline or a confirmed HCT of &gt;48%, depending on which was lower. Key secondary endpoints included the proportion of patients who achieved the primary endpoint and remained free from progression at week&nbsp;48, as well as the proportion of patients achieving complete haematological remission at week&nbsp;32.</p><p>&nbsp;</p><p>The study met its primary objective and a higher proportion of patients in the Jakavi group achieved the primary composite endpoint and each of its individual components. Significantly more patients treated with Jakavi (23%) achieved a primary response (p&lt;0.0001) compared to BAT (0.9%). Haematocrit control was achieved in 60% of patients in the Jakavi arm compared to 18.8% in the BAT arm and a &ge;35% reduction in spleen volume was achieved in 40% of patients in the Jakavi arm compared to 0.9% in the BAT arm (Figure&nbsp;1).</p><p>&nbsp;</p><p>Both key secondary endpoints were also met. The proportion of patients achieving a complete haematological remission was 23.6% on Jakavi compared to 8.0% on BAT (p=0.0013) and the proportion of patients achieving a durable primary response at week&nbsp;48 was 20% on Jakavi and 0.9% on BAT (p&lt;0.0001).</p><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients achieving the primary endpoint and components of the primary endpoint at week&nbsp;32</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
   o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
   stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Chart_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
   style='width:367.5pt;height:231.75pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQAIpCpGOwEAAJkDAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyTTW7DIBCF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">
   <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
    o:title="" croptop="-7640f" cropbottom="-5302f" cropleft="-347f"
    cropright="-1195f"/>
  </v:shape><![endif]--><img width="490" height="309" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>Symptom burden was assessed using the MPN-SAF total symptom score (TSS) electronic patient diary, which consisted of 14&nbsp;questions. At week&nbsp;32, 49% and 64% of patients treated with ruxolitinib achieved a &ge;50% reduction in TSS-14 and TSS-5, respectively, compared to only 5% and 11% of patients on BAT.</p><p>&nbsp;</p><p>Treatment benefit perception was measured by the Patient Global Impression of Change (PGIC) questionnaire. 66% of patients treated with ruxolitinib compared to 19% treated with BAT reported an improvement as early as four weeks after beginning treatment. Improvement in perception of treatment benefit was also higher in patients treated with ruxolitinib at week&nbsp;32 (78% versus 33%).</p><p>Additional analyses from the RESPONSE study to assess durability of response were conducted at week&nbsp;80 and week&nbsp;256 following randomisation. Out of 25&nbsp;patients who had achieved primary response at week&nbsp;32, 3&nbsp;patients had progressed by week&nbsp;80 and 6&nbsp;patients by week&nbsp;256. The probability to have maintained a response from week&nbsp;32 up to week&nbsp;80 and week&nbsp;256 was 92% and 74%, respectively (see Table&nbsp;8).</p><p><strong>Table&nbsp;8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Durability of primary response in the RESPONSE study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Week&nbsp;32</p></td><td style="vertical-align:top"><p>Week&nbsp;80</p></td><td style="vertical-align:top"><p>Week&nbsp;256</p></td></tr><tr><td style="vertical-align:top"><p>Primary response achieved at week 32*</p><p>n/N (%)</p></td><td style="vertical-align:top"><p>25/110 (23%)</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>n/a</p></td></tr><tr><td style="vertical-align:top"><p>Patients maintaining primary response</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>22/25</p></td><td style="vertical-align:top"><p>19/25</p></td></tr><tr><td style="vertical-align:top"><p>Probability of maintaining primary response</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>92%</p></td><td style="vertical-align:top"><p>74%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* According to the primary response composite endpoint criteria: absence of phlebotomy eligibility (HCT control) and a &ge;35% reduction in spleen volume from baseline.</p><p>n/a: not applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>A second randomised, open label, active-controlled phase&nbsp;3b study (RESPONSE&nbsp;2) was conducted in 149 PV patients who were resistant to, or intolerant of, hydroxyurea but without palpable splenomegaly. The primary endpoint defined as the proportion of patients achieving HCT control (absence of phlebotomy eligibility) at week&nbsp;28 was met (62.2% in the Jakavi arm versus 18.7% in the BAT arm). The key secondary endpoint defined as the proportion of patients achieving complete haematological remission at week&nbsp;28 was also met (23.0% in the Jakavi arm versus 5.3% in the BAT arm).</p><p>&nbsp;</p><p><em><u>Graft-versus-host disease</u></em></p><p>Two randomised phase&nbsp;3, open-label, multi-centre studies investigated Jakavi in patients 12&nbsp;years of age and older with acute GvHD (REACH2) and chronic GvHD (REACH3) after allogeneic haematopoietic stem cell transplantation (alloSCT) and insufficient response to corticosteroids and/or other systemic therapies. The starting dose of Jakavi was 10&nbsp;mg twice daily.</p><p>&nbsp;</p><p><em>Acute graft-versus-host disease</em></p><p>In REACH2, 309&nbsp;patients with grade&nbsp;II to IV corticosteroid-refractory, acute GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of acute GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had progression after at least 3&nbsp;days, failed to achieve a response after 7&nbsp;days or failed corticosteroid taper.</p><p>&nbsp;</p><p>BAT was selected by the investigator on a patient-by-patient basis and included anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab.</p><p>&nbsp;</p><p>In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Ruxolitinib was added to continued use of corticosteroids and/or calcineurin inhibitors (CNIs) such as cyclosporine or tacrolimus and/or topical or inhaled corticosteroid therapies per institutional guidelines.</p><p>&nbsp;</p><p>Patients who received one prior systemic treatment other than corticosteroids and CNI for acute GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for acute GvHD was allowed to continue only if used for acute GvHD prophylaxis (i.e. started before the acute GvHD diagnosis) as per common medical practice.</p><p>&nbsp;</p><p>Patients on BAT could cross over to ruxolitinib after day&nbsp;28 if they met the following criteria:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Failed to meet the primary endpoint response definition (complete response [CR] or partial response [PR]) at day&nbsp;28; OR</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lost the response thereafter and met criteria for progression, mixed response, or no response, necessitating new additional systemic immunosuppressive treatment for acute GvHD, AND</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Did not have signs/symptoms of chronic GvHD.</p><p>&nbsp;</p><p>Tapering of Jakavi was allowed after the day&nbsp;56 visit for patients with treatment response.</p><p>&nbsp;</p><p>Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 54&nbsp;years (range 12 to 73&nbsp;years). The study included 2.9% adolescent, 59.2% male and 68.9% white patients. The majority of enrolled patients had malignant underlying disease.</p><p>&nbsp;</p><p>The severity of acute GvHD was grade&nbsp;II in 34% and 34%, grade&nbsp;III in 46% and 47%, and grade&nbsp;IV in 20% and 19% of the Jakavi and BAT arms, respectively.</p><p>&nbsp;</p><p>The reasons for patients&rsquo; insufficient response to corticosteroids in the Jakavi and BAT arms were i) failure in achieving a response after 7&nbsp;days of corticosteroid treatment (46.8% and 40.6%, respectively), ii) failure of corticosteroid taper (30.5% and 31.6%, respectively) or iii) disease progression after 3&nbsp;days of treatment (22.7% and 27.7%, respectively).</p><p>&nbsp;</p><p>Among all patients, the most common organs involved in acute GvHD were skin (54.0%) and lower gastrointestinal tract (68.3%). More patients in the Jakavi arm had acute GvHD involving skin (60.4%) and liver (23.4%), compared to the BAT arm (skin: 47.7% and liver: 16.1%).</p><p>&nbsp;</p><p>The most frequently used prior systemic acute GvHD therapies were corticosteroids+CNIs (49.4% in the Jakavi arm and 49.0% in the BAT arm).</p><p>&nbsp;</p><p>The primary endpoint was the overall response rate (ORR) on day&nbsp;28, defined as the proportion of patients in each arm with a complete response (CR) or a partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment following the criteria by Harris et al. (2016).</p><p>&nbsp;</p><p>The key secondary endpoint was the proportion of patients who achieved a CR or PR at day&nbsp;28 and maintained a CR or PR at day&nbsp;56.</p><p>&nbsp;</p><p>REACH2 met its primary objective. ORR at day&nbsp;28 of treatment was higher in the Jakavi arm (62.3%) compared to the BAT arm (39.4%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p&lt;0.0001, two-sided, OR: 2.64; 95% CI: 1.65, 4.22).</p><p>&nbsp;</p><p>There was also a higher proportion of complete responders in the Jakavi arm (34.4%) compared to BAT arm (19.4%).</p><p>&nbsp;</p><p>Day-28 ORR was 76% for grade&nbsp;II GvHD, 56% for grade&nbsp;III GvHD, and 53% for grade&nbsp;IV GvHD in the Jakavi arm, and 51% for grade&nbsp;II GvHD, 38% for grade&nbsp;III GvHD, and 23% for grade&nbsp;IV GvHD in the BAT arm.</p><p>&nbsp;</p><p>Among the non-responders at day&nbsp;28 in the Jakavi and BAT arms, 2.6% and 8.4% had disease progression, respectively.</p><p>&nbsp;</p><p>Overall results are presented in Table&nbsp;9.</p><p>&nbsp;</p><p><strong>Table&nbsp;9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overall response rate at day&nbsp;28 in REACH2</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Jakavi</strong></p><p><strong>N=154</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BAT</strong></p><p><strong>N=155</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall response</p></td><td style="vertical-align:top"><p>96 (62.3)</p></td><td style="vertical-align:top"><p>54.2, 70.0</p></td><td style="vertical-align:top"><p>61 (39.4)</p></td><td style="vertical-align:top"><p>31.6, 47.5</p></td></tr><tr><td style="vertical-align:top"><p>OR (95% CI)</p></td><td colspan="4" style="vertical-align:top"><p>2.64 (1.65, 4.22)</p></td></tr><tr><td style="vertical-align:top"><p>p-value (2-sided)</p></td><td colspan="4" style="vertical-align:top"><p>p &lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td colspan="2" style="vertical-align:top"><p>53 (34.4)</p></td><td colspan="2" style="vertical-align:top"><p>30 (19.4)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td colspan="2" style="vertical-align:top"><p>43 (27.9)</p></td><td colspan="2" style="vertical-align:top"><p>31 (20.0)</p></td></tr></tbody></table><p>&nbsp;</p><p>The study met its key secondary endpoint based on the primary data analysis (data cut-off date: 25-Jul-2019). Durable ORR at day&nbsp;56 was 39.6% (95% CI: 31.8, 47.8) in the Jakavi arm and 21.9% (95% CI: 15.7, 29.3) in the BAT arm. There was a statistically significant difference between the two treatment arms (OR: 2.38; 95% CI: 1.43, 3.94; p=0.0007). The proportion of patients with a CR was 26.6% in the Jakavi arm versus 16.1% in the BAT arm. Overall, 49&nbsp;patients (31.6%) originally randomised to the BAT arm crossed over to the Jakavi arm.</p><p>&nbsp;</p><p><em>Chronic graft-versus-host disease</em></p><p>In REACH3, 329&nbsp;patients with moderate or severe corticosteroid-refractory, chronic GvHD were randomised 1:1 to Jakavi or BAT. Patients were stratified by severity of chronic GvHD at the time of randomisation. Corticosteroid refractoriness was determined when patients had lack of response or disease progression after 7&nbsp;days, or had disease persistence for 4&nbsp;weeks or failed corticosteroid taper twice.</p><p>&nbsp;</p><p>BAT was selected by the investigator on a patient-by-patient basis and included extracorporeal photopheresis (ECP), low dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, or ibrutinib.</p><p>&nbsp;</p><p>In addition to Jakavi or BAT, patients could have received standard allogeneic stem cell transplantation supportive care including anti-infective medicinal products and transfusion support. Continued use of corticosteroids and CNIs such as cyclosporine or tacrolimus and topical or inhaled corticosteroid therapies were allowed per institutional guidelines.</p><p><em>&nbsp;</em></p><p>Patients who received one prior systemic treatment other than corticosteroids and/or CNI for chronic GvHD were eligible for inclusion in the study. In addition to corticosteroids and CNI, prior systemic medicinal product for chronic GvHD was allowed to continue only if used for chronic GvHD prophylaxis (i.e. started before the chronic GvHD diagnosis) as per common medical practice.</p><p>&nbsp;</p><p>Patients on BAT could cross over to ruxolitinib on cycle&nbsp;7 day&nbsp;1 and thereafter due to disease progression, mixed response, or unchanged response, due to toxicity to BAT, or due to chronic GvHD flare.</p><p>&nbsp;</p><p>Efficacy in patients that transition from active acute GvHD to chronic GvHD without tapering off corticosteroids and any systemic treatment is unknown. Efficacy in acute or chronic GvHD after donor lymphocyte infusion (DLI) and in patients who did not tolerate steroid treatment is unknown.</p><p>Tapering of Jakavi was allowed after the cycle&nbsp;7 day&nbsp;1 visit.</p><p>Baseline demographics and disease characteristics were balanced between the two treatment arms. The median age was 49&nbsp;years (range 12 to 76&nbsp;years). The study included 3.6% adolescent, 61.1% male and 75.4% white patients. The majority of enrolled patients had malignant underlying disease.</p><p>The severity at diagnosis of corticosteroid-refractory chronic GvHD was balanced between the two treatment arms, with 41% and 45% moderate, and 59% and 55% severe, in the Jakavi and the BAT arms, respectively.</p><p>Patients&rsquo; insufficient response to corticosteroids in the Jakavi and BAT arm were characterised by i) a lack of response or disease progression after corticosteroid treatment for at least 7&nbsp;days at 1&nbsp;mg/kg/day of prednisone equivalents (37.6% and 44.5%, respectively), ii) disease persistence after 4&nbsp;weeks at 0.5&nbsp;mg/kg/day (35.2% and 25.6%), or iii) corticosteroid dependency (27.3% and 29.9%, respectively).</p><p>Among all patients, 73% and 45% had skin and lung involvement in the Jakavi arm, compared to 69% and 41% in the BAT arm.</p><p>The most frequently used prior systemic chronic GvHD therapies were corticosteroids only (43% in the Jakavi arm and 49% in the BAT arm) and corticosteroids+CNIs (41% patients in the Jakavi arm and 42% in the BAT arm).</p><p>The primary endpoint was the ORR on day&nbsp;1 of cycle&nbsp;7, defined as the proportion of patients in each arm with a CR or a PR without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response based on investigator assessment per National Institutes of Health (NIH) criteria.</p><p>&nbsp;</p><p>A key secondary endpoint was failure free survival (FFS), a composite time to event endpoint, incorporating the earliest of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for chronic GvHD.</p><p>&nbsp;</p><p>REACH3 met its primary objective. At the time of primary analysis (data cut-off date: 08-May-2020), the ORR at week&nbsp;24 was higher in the Jakavi arm (49.7%) compared to the BAT arm (25.6%). There was a statistically significant difference between the treatment arms (stratified Cochrane-Mantel-Haenszel test p&lt;0.0001, two-sided, OR: 2.99; 95% CI: 1.86, 4.80). Results are presented in Table&nbsp;10.</p><p>&nbsp;</p><p>Among the non-responders at cycle&nbsp;7 day&nbsp;1 in the Jakavi and BAT arms, 2.4% and 12.8% had disease progression, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overall response rate at cycle&nbsp;7 day&nbsp;1 in REACH3</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Jakavi</strong></p><p><strong>N=165</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>BAT</strong></p><p><strong>N=164</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Overall response</p></td><td style="vertical-align:top"><p>82 (49.7)</p></td><td style="vertical-align:top"><p>41.8, 57.6</p></td><td style="vertical-align:top"><p>42 (25.6)</p></td><td style="vertical-align:top"><p>19.1, 33.0</p></td></tr><tr><td style="vertical-align:top"><p>OR (95% CI)</p></td><td colspan="4" style="vertical-align:top"><p>2.99 (1.86, 4.80)</p></td></tr><tr><td style="vertical-align:top"><p>p-value (2-sided)</p></td><td colspan="4" style="vertical-align:top"><p>p&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td colspan="2" style="vertical-align:top"><p>11 (6.7)</p></td><td colspan="2" style="vertical-align:top"><p>5 (3.0)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td colspan="2" style="vertical-align:top"><p>71 (43.0)</p></td><td colspan="2" style="vertical-align:top"><p>37 (22.6)</p></td></tr></tbody></table><p>&nbsp;</p><p>The key secondary endpoint, FFS, demonstrated a statistically significant 63% risk reduction of Jakavi versus BAT (HR: 0.370; 95% CI: 0.268, 0.510<em>, </em>p&lt;0.0001). At 6-months, the majority of FFS events were &ldquo;addition or initiation of another systemic therapy for cGvHD&rdquo; (probability of that event was 13.4% vs 48.5% for the Jakavi and the BAT arms, respectively). Results for &ldquo;relapse of underlying disease&rdquo; and non-relapse mortality (NRM) were 2.46% vs 2.57% and 9.19% vs 4.46%, in the Jakavi and the BAT arms, respectively. No difference of cumulative incidences between treatment arms was observed when focusing on NRM only.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Jakavi in all subsets of the paediatric population for the treatment of MF and PV. In GvHD paediatric patients (12&nbsp;years of age and older), the safety and efficacy of Jakavi are supported by evidence from the randomised phase&nbsp;3 studies REACH2 and REACH3 (see section&nbsp;4.2 for information on paediatric use). In REACH2, responses were observed at day&nbsp;28 in 4/5 adolescent patients with acute GvHD (3 had CR and 1 had PR) in the ruxolitinib arm and in 3/4 adolescent patients (3 had CR) in the BAT arm. In REACH3, responses were observed at cycle&nbsp;7 day&nbsp;1 in 3/4 adolescent patients with chronic GvHD (all had PR) in the ruxolitinib arm and in 2/8 adolescent patients (both had PR) in the BAT arm.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u>Absorption</u></p><p>&nbsp;</p><p>Ruxolitinib is a Biopharmaceutical Classification System (BCS) class&nbsp;1 compound, with high permeability, high solubility and rapid dissolution characteristics. In clinical studies, ruxolitinib is rapidly absorbed after oral administration with maximal plasma concentration (C<sub>max</sub>) achieved approximately 1&nbsp;hour post‑dose. Based on a human mass balance study, oral absorption of ruxolitinib, as ruxolitinib or metabolites formed under first‑pass, is 95% or greater. Mean ruxolitinib C<sub>max</sub> and total exposure (AUC) increased proportionally over a single dose range of 5‑200&nbsp;mg. There was no clinically relevant change in the pharmacokinetics of ruxolitinib upon administration with a high‑fat meal. The mean C<sub>max</sub> was moderately decreased (24%) while the mean AUC was nearly unchanged (4% increase) on dosing with a high‑fat meal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean volume of distribution at steady state is approximately 75&nbsp;litres in MF and PV patients. At clinically relevant concentrations of ruxolitinib, binding to plasma proteins <em>in vitro</em> is approximately 97%, mostly to albumin. A whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood‑brain barrier.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Ruxolitinib is mainly metabolised by CYP3A4 (&gt;50%), with additional contribution from CYP2C9. Parent compound is the predominant entity in human plasma, representing approximately 60% of the drug‑related material in circulation. Two major and active metabolites are present in plasma representing 25% and 11% of parent AUC. These metabolites have one half to one fifth of the parent JAK‑related pharmacological activity. The sum total of all active metabolites contributes to 18% of the overall pharmacodynamics of ruxolitinib. At clinically relevant concentrations, ruxolitinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 and is not a potent inducer of CYP1A2, CYP2B6 or CYP3A4 based on <em>in vitro</em> studies. <em>In vitro</em> data indicate that ruxolitinib may inhibit P‑gp and BCRP.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Ruxolitinib is mainly eliminated through metabolism. The mean elimination half‑life of ruxolitinib is approximately 3&nbsp;hours. Following a single oral dose of [<sup>14</sup>C]‑labelled ruxolitinib in healthy adult subjects, elimination was predominately through metabolism, with 74% of radioactivity excreted in urine and 22% via faeces. Unchanged parent substance accounted for less than 1% of the excreted total radioactivity.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>Dose proportionality was demonstrated in the single and multiple dose studies.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Effects of body surface area, age, gender or race</u></em></p><p>Based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race. In a population pharmacokinetic evaluation in MF patients, no relationship was apparent between oral clearance and patient age or race. The predicted oral clearance was 17.7&nbsp;l/h in women and 22.1&nbsp;l/h in men, with 39% inter‑subject variability in MF patients. Clearance was 12.7&nbsp;l/h in PV patients, with a 42% inter‑subject variability and no relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in PV patients. Clearance was 10.4&nbsp;l/h in patients with acute GvHD and 7.8&nbsp;l/h in patients with chronic GvHD, with a 49% inter‑subject variability. No relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in GvHD patients. Exposure was increased in GvHD patients with a low body surface area (BSA). In subjects with a BSA of 1&nbsp;m<sup>2</sup>, 1.25&nbsp;m<sup>2</sup> and 1.5&nbsp;m<sup>2</sup>, the predicted mean exposure (AUC) was respectively 31%, 22% and 12% higher than the typical adult (1.79&nbsp;m<sup>2</sup>).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The pharmacokinetics of Jakavi in paediatric patients &lt;18&nbsp;years old with MF and PV have not been established. The pharmacokinetics profile observed in adolescent patients with acute or chronic GvHD was comparable to the overall patient population (see section&nbsp;5.1, &ldquo;Paediatric population&rdquo;). Ruxolitinib has not yet been evaluated in paediatric patients with acute or chronic GvHD below the age of 12.</p><p><em><u>Renal impairment</u></em></p><p>Renal function was determined using both Modification of Diet in Renal Disease (MDRD) and urinary creatinine. Following a single ruxolitinib dose of 25&nbsp;mg, the exposure of ruxolitinib was similar in subjects with various degrees of renal impairment and in those with normal renal function. However, plasma AUC values of ruxolitinib metabolites tended to increase with increasing severity of renal impairment, and were most markedly increased in the subjects with severe renal impairment. It is unknown whether the increased metabolite exposure is of safety concern. A dose modification is recommended in patients with severe renal impairment and end‑stage renal disease (see section&nbsp;4.2). Dosing only on dialysis days reduces the metabolite exposure, but also the pharmacodynamic effect, especially on the days between dialysis.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Following a single ruxolitinib dose of 25&nbsp;mg in patients with varying degrees of hepatic impairment, the mean AUC for ruxolitinib was increased in patients with mild, moderate and severe hepatic impairment by 87%, 28% and 65%, respectively, compared to patients with normal hepatic function. There was no clear relationship between AUC and the degree of hepatic impairment based on Child‑Pugh scores. The terminal elimination half‑life was prolonged in patients with hepatic impairment compared to healthy controls (4.1‑5.0&nbsp;hours versus 2.8&nbsp;hours). A dose reduction of approximately 50% is recommended for MF and PV patients with hepatic impairment (see section&nbsp;4.2).</p><p>&nbsp;</p><p>In GvHD patients with hepatic impairment not related to GvHD, the starting dose of ruxolitinib should be reduced by 50%.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity and reproductive toxicity studies and in a carcinogenicity study. Target organs associated with the pharmacological action of ruxolitinib in repeated dose studies include bone marrow, peripheral blood and lymphoid tissues. Infections generally associated with immunosuppression were noted in dogs. Adverse decreases in blood pressure along with increases in heart rate were noted in a dog telemetry study, and an adverse decrease in minute volume was noted in a respiratory study in rats. The margins (based on unbound C<sub>max</sub>) at the non‑adverse level in the dog and rat studies were 15.7‑fold and 10.4‑fold greater, respectively, than the maximum human recommended dose of 25&nbsp;mg twice daily. No effects were noted in an evaluation of the neuropharmacological effects of ruxolitinib.</p><p>&nbsp;</p><p>In juvenile rat studies, administration of ruxolitinib resulted in effects on growth and bone measures. Reduced bone growth was observed at doses &ge;5&nbsp;mg/kg/day when treatment started on postnatal day&nbsp;7 (comparable to human newborn) and at &ge;15&nbsp;mg/kg/day when treatment started on postnatal days&nbsp;14 or 21 (comparable to human infant, 1&ndash;3&nbsp;years). Fractures and early termination of rats were observed at doses &ge;30&nbsp;mg/kg/day when treatment was started on postnatal day&nbsp;7. Based on unbound AUC, the exposure at the NOAEL (no observed adverse effect level) in juvenile rats treated as early as postnatal day&nbsp;7 was 0.3‑fold that of adult patients at 25&nbsp;mg twice daily, while reduced bone growth and fractures occurred at exposures that were 1.5- and 13-fold that of adult patients at 25&nbsp;mg twice daily, respectively. The effects were generally more severe when administration was initiated earlier in the postnatal period. Other than bone development, the effects of ruxolitinib in juvenile rats were similar to those in adult rats. Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.</p><p>&nbsp;</p><p>Ruxolitinib decreased foetal weight and increased post‑implantation loss in animal studies. There was no evidence of a teratogenic effect in rats and rabbits. However, the exposure margins compared to the highest clinical dose were low and the results are therefore of limited relevance for humans. No effects were noted on fertility. In a pre‑ and post‑natal development study, a slightly prolonged gestation period, reduced number of implantation sites, and reduced number of pups delivered were observed. In the pups, decreased mean initial body weights and short period of decreased mean body weight gain were observed. In lactating rats, ruxolitinib and/or its metabolites were excreted into the milk with a concentration that was 13‑fold higher than the maternal plasma concentration. Ruxolitinib was not mutagenic or clastogenic. Ruxolitinib was not carcinogenic in the Tg.rasH2 transgenic mouse model.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Cellulose, microcrystalline</p><p>Magnesium stearate</p><p>Silica, colloidal anhydrous</p><p>Sodium starch glycolate (Type A)</p><p>Povidone K30</p><p>Hydroxypropylcellulose 300 to 600 cps</p><p>Lactose monohydrate</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PCTFE/Aluminium blister packs containing 14 or 56&nbsp;tablets or multipacks containing 168 (3&nbsp;packs of 56)&nbsp;tablets.</p><p>&nbsp;</p><p>Not all pack sizes or types may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA on Apr/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>